ATE348633T1 - Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen - Google Patents

Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen

Info

Publication number
ATE348633T1
ATE348633T1 AT03738331T AT03738331T ATE348633T1 AT E348633 T1 ATE348633 T1 AT E348633T1 AT 03738331 T AT03738331 T AT 03738331T AT 03738331 T AT03738331 T AT 03738331T AT E348633 T1 ATE348633 T1 AT E348633T1
Authority
AT
Austria
Prior art keywords
nucleic acid
immune response
boosting
protein
liposomes
Prior art date
Application number
AT03738331T
Other languages
English (en)
Inventor
Andrew David Bacon
Peter Laing
Gregory Gregoriadis
Wilson R Li Caparros-Wanderley
Original Assignee
Lipoxen Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipoxen Technologies Ltd filed Critical Lipoxen Technologies Ltd
Application granted granted Critical
Publication of ATE348633T1 publication Critical patent/ATE348633T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03738331T 2002-07-05 2003-07-07 Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen ATE348633T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02254733 2002-07-05

Publications (1)

Publication Number Publication Date
ATE348633T1 true ATE348633T1 (de) 2007-01-15

Family

ID=30011235

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03738331T ATE348633T1 (de) 2002-07-05 2003-07-07 Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen

Country Status (10)

Country Link
US (5) US7604803B2 (de)
EP (1) EP1519745B1 (de)
JP (1) JP4294584B2 (de)
CN (1) CN100340289C (de)
AT (1) ATE348633T1 (de)
AU (1) AU2003244855A1 (de)
DE (1) DE60310562T2 (de)
ES (1) ES2279127T3 (de)
RU (1) RU2311911C2 (de)
WO (1) WO2004004758A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6740323B1 (en) * 1999-11-24 2004-05-25 Chiron Corporation HBV/HCV virus-like particle
EP1519745B1 (de) * 2002-07-05 2006-12-20 Lipoxen Technologies Limited Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen
WO2006071989A2 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
TW200800235A (en) * 2005-10-18 2008-01-01 Otsuka Pharma Co Ltd Carrier composition for nucleic acid transport
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
AU2009236306B2 (en) 2008-04-17 2015-04-02 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
EP2184054A1 (de) 2008-11-08 2010-05-12 Lipoxen Technologies Limited SiRNA-Abgabe
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
CN102482666B (zh) * 2009-07-06 2017-02-08 变异生物技术公司 制备囊泡的方法和由其产生的制剂
CN102068698A (zh) * 2009-11-24 2011-05-25 深圳先进技术研究院 纳米疫苗及其制备方法
RU2448685C2 (ru) * 2009-11-30 2012-04-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза
ES2646669T3 (es) 2010-07-06 2017-12-14 Glaxosmithkline Biologicals Sa Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
SI2591114T1 (sl) 2010-07-06 2016-10-28 Glaxosmithkline Biologicals S.A. Imunizacija velikih sesalcev z majhnimi odmerki RNA
WO2012006368A2 (en) * 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
CN103096922B (zh) 2010-07-06 2019-08-06 变异生物技术公司 用于治疗流行性感冒的组合物和方法
AU2011276234B2 (en) 2010-07-06 2016-02-25 Glaxosmithkline Biologicals S.A. Liposomes with lipids having an advantageous pKa- value for RNA delivery
WO2012031043A1 (en) 2010-08-31 2012-03-08 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna
EP3520813B1 (de) 2010-10-11 2023-04-19 GlaxoSmithKline Biologicals S.A. Antigenfreisetzungsplattformen
BR112013017939B1 (pt) 2011-01-13 2022-11-16 Variation Biotechnologies Inc Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma
LT2726883T (lt) * 2011-06-29 2018-06-11 Cellestis Limited Padidinto jautrumo ląstelių imuninio atsako įvertinimo būdas
CA2841047A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
EP3854413A1 (de) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogene kombinationszusammensetzungen und ihre verwendung
EP2802353A4 (de) 2012-01-12 2015-12-02 Variation Biotechnologies Inc Zusammensetzungen und verfahren zur behandlung von virusinfektionen
CN104244984B (zh) 2012-01-27 2020-03-31 变异生物技术公司 用于治疗剂的方法和组合物
AU2013246870B2 (en) * 2012-04-11 2016-06-23 Lipoxen Technologies Limited Liposomes containing oligopeptide fragments of myelin basic protein, a pharmaceutical composition and a method for treatment of multiple sclerosis
US10286064B2 (en) 2012-06-15 2019-05-14 Pds Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
TWI672149B (zh) 2012-09-21 2019-09-21 美商Ｐｄｓ生技公司 改良之疫苗組成物及使用方法
CN104922666A (zh) * 2014-03-21 2015-09-23 中国科学院苏州纳米技术与纳米仿生研究所 超小氧化石墨烯-金纳米粒子免疫复合物及其制备方法
WO2016045732A1 (en) * 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
EP4092112A1 (de) 2015-11-13 2022-11-23 PDS Biotechnology Corporation Lipide als synthetische vektoren zur verbesserung der antigenverarbeitung und präsentation ex-vivo in der dendritischen zelltherapie
AU2018378588A1 (en) 2017-12-05 2020-06-25 Pds Biotechnology Corporation Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes
US12536001B1 (en) 2025-05-21 2026-01-27 Dropbox, Inc. Generating, managing, and organizing persisted data elements based on one or more states of an agent

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
CA2244110A1 (en) * 1996-02-12 1997-08-14 Cobra Therapeutics Limited Novel methods of vaccination and vaccines thereof comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
ATE395904T1 (de) * 1996-09-13 2008-06-15 Lipoxen Technologies Ltd Liposome
DK1007546T3 (da) * 1997-08-27 2009-03-16 Novartis Vaccines & Diagnostic Molekylære mimetika af meningokok-B-epitoper
GB9726555D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
US6166177A (en) * 1998-12-08 2000-12-26 Corixa Corporation Compounds and methods for the treatment and diagnosis of chlamydial infection
CA2386024A1 (en) * 1999-10-01 2001-04-12 Lipoxen Technologies Limited Liposome-entrapped dna oral vaccines
CN1301572A (zh) * 1999-10-28 2001-07-04 上海生物制品研究所 用于疫苗的佐剂组合物
EP1237541B1 (de) 1999-12-13 2004-09-01 Lipoxen Technologies Limited Liposomen enthaltend einen komplex aus polyanion und calciumphosphat
ATE341310T1 (de) 2000-02-04 2006-10-15 Lipoxen Technologies Ltd Dehydratisierungs-/rehydratisierungsverfahren zur herstellung von liposome
US7285289B2 (en) * 2002-04-12 2007-10-23 Nagy Jon O Nanoparticle vaccines
EP1519745B1 (de) * 2002-07-05 2006-12-20 Lipoxen Technologies Limited Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen

Also Published As

Publication number Publication date
CN1665529A (zh) 2005-09-07
RU2004137791A (ru) 2006-01-20
US20170049702A1 (en) 2017-02-23
US9486510B2 (en) 2016-11-08
DE60310562T2 (de) 2007-10-11
EP1519745B1 (de) 2006-12-20
JP2005535653A (ja) 2005-11-24
DE60310562D1 (de) 2007-02-01
US20100080844A1 (en) 2010-04-01
US7604803B2 (en) 2009-10-20
US8828405B2 (en) 2014-09-09
JP4294584B2 (ja) 2009-07-15
AU2003244855A1 (en) 2004-01-23
US8075896B2 (en) 2011-12-13
CN100340289C (zh) 2007-10-03
ES2279127T3 (es) 2007-08-16
RU2311911C2 (ru) 2007-12-10
US20120121690A1 (en) 2012-05-17
EP1519745A1 (de) 2005-04-06
US20140341980A1 (en) 2014-11-20
US20050220858A1 (en) 2005-10-06
WO2004004758A1 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
DE60310562D1 (de) Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen
CY1121353T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
DE60235810D1 (de) Verfahren zur herstellung von l-aminosäuren durch enterobacteriaceae-stämme mit verstärkter expression des fba-gens
BR112021017801A2 (pt) Anticorpos biespecíficos anti-vbeta17/anti-cd123
DE50312217D1 (de) Verfahren zur herstellung von 1-olefinen durch katalytische spaltung von 1-alkoxyalkanen
DE60139542D1 (de) Methoden zur herstellung humaner monoklonaler antikörper
SG153874A1 (en) Neutralizing epitope-based growth enhancing vaccine
ATE61228T1 (de) Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff.
ATE125157T1 (de) Methoden und zusammensetzungen zur impfung gegen hiv.
ATE378403T1 (de) Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
DE50303749D1 (de) Verfahren zur herstellung von phthalocyaninpigmentzubereitungen
BR0017052B1 (pt) Método para a projeção de um constructo poliepitópico e constructo poliepitópico preparado pelo referido método
ATE473236T1 (de) Antigene von piscirickettsia salmonis und deren verwendung
ATE493497T1 (de) Verfahren zur herstellung von oligopeptiden
ATE204851T1 (de) Verfahren zur herstellung von retrovial protease hemmenden zwischenprodukten
DE69940731D1 (de) Zusammensetzungen und verfahren zur modulation einer immunantwort auf ein antigen durch verabreichung von zytokine-beladenen zellen
ATE424217T1 (de) Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen
ATE417112T1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
DE60309847D1 (de) Zwischenprodukte und verfahren zur herstellung von heptapeptid-oxytocinanaloga
TR27329A (tr) Yeni metazoan parazit antigenler, bunlari kodlayan nükleik asidler.
ATE528280T1 (de) Verfahren zur herstellung von triethanolamin
ATE445017T1 (de) Methode zur herstellung eines polypeptides, einer rna oder einer anderen verbindung in tumorgewebe
DE60108105D1 (de) Verfahren zur Herstellung von 5-substituierten Isobenzofuranen
DE60140192D1 (de) VERFAHREN ZUR HERSTELLUNG VON ANTIKöRPERN DURCH GENIMMUNISIERUNG
ATE386015T1 (de) Verfahren zur herstellung von alkyl-n-(3- dimethylamino)alkylcarbamaten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties